JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Woolverton, W. L.
Right arrow Articles by Kozikowski, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Woolverton, W. L.
Right arrow Articles by Kozikowski, A.

Vol. 303, Issue 1, 211-217, October 2002

Reinforcing Strength of a Novel Dopamine Transporter Ligand: Pharmacodynamic and Pharmacokinetic Mechanisms

W. L. Woolverton, R. Ranaldi, Z. Wang, G. A. Ordway, I. A. Paul, P. Petukhov and A. Kozikowski

Department of Psychiatry, University of Mississippi Medical Center, Jackson, Mississippi (W.L.W., R.R., Z.W., G.A.O., I.A.P.); and Departments of Neurology and Pharmacology, Georgetown University Medical Center, Washington, DC (P.P., A.K.)

Drugs that block dopamine uptake often function as positive reinforcers but can differ along the dimension of strength or effectiveness as a positive reinforcer. The present study was designed to examine pharmacological mechanisms that might contribute to differences in reinforcing strength between the piperidine-based cocaine analog (+)-methyl 4beta -(4-chlorophenyl)-1-methylpiperidine-3-alpha -carboxylate [(+)-CPCA] and cocaine. Drugs were made available to rhesus monkeys (n = 5) for i.v. self-administration under a progressive ratio schedule. Both compounds maintained responding with sigmoidal or biphasic dose-response functions (0.1-1.0 mg/kg/injection). (+)-CPCA was one-fourth as potent as cocaine and maintained fewer injections per session, at maximum. For in vitro binding in monkey brain tissue, (+)-CPCA was about one-half as potent as cocaine at the dopamine transporter (DAT), and the two compounds had similar affinities at the norepinephrine transporter. (+)-CPCA was less than 1/10 as potent as cocaine at the serotonin transporter. In ex vivo binding in rat striatum, occupancy of the DAT increased directly with dose to a maximum of approximately 80% for both compounds, and (+)-CPCA was about one-fourth as potent as cocaine. Ex vivo DAT occupancy was significantly higher for cocaine than (+)-CPCA at 2 min after injection but similar at other times. Thus, the primary differences between these compounds were in serotonin transporter affinity and the kinetics of DAT binding. These results suggest that (+)-CPCA is a weaker positive reinforcer than cocaine because it has a slower onset of action over the first few minutes after i.v. injection.


0022-3565/02/3031-0211$07.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
T. Hiranita, P. L. Soto, A. H. Newman, and J. L. Katz
Assessment of Reinforcing Effects of Benztropine Analogs and Their Effects on Cocaine Self-Administration in Rats: Comparisons with Monoamine Uptake Inhibitors
J. Pharmacol. Exp. Ther., May 1, 2009; 329(2): 677 - 686.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
O. T. Ukairo, C. D. Bondi, A. H. Newman, S. S. Kulkarni, A. P. Kozikowski, S. Pan, and C. K. Surratt
Recognition of Benztropine by the Dopamine Transporter (DAT) Differs from That of the Classical Dopamine Uptake Inhibitors Cocaine, Methylphenidate, and Mazindol as a Function of a DAT Transmembrane 1 Aspartic Acid Residue
J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 575 - 583.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. A. Lile, Z. Wang, W. L. Woolverton, J. E. France, T. C. Gregg, H. M. L. Davies, and M. A. Nader
The Reinforcing Efficacy of Psychostimulants in Rhesus Monkeys: The Role of Pharmacokinetics and Pharmacodynamics
J. Pharmacol. Exp. Ther., October 1, 2003; 307(1): 356 - 366.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. P. Kozikowski, K. M. Johnson, O. Deschaux, B. C. Bandyopadhyay, G. L. Araldi, G. Carmona, P. Munzar, M. P. Smith, R. L. Balster, P. M. Beardsley, et al.
Mixed Cocaine Agonist/Antagonist Properties of (+)-Methyl 4beta -(4-Chlorophenyl)-1-methylpiperidine-3alpha -carboxylate, a Piperidine-Based Analog of Cocaine
J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 143 - 150.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.